Efficacy and safety of AZD7009 in the treatment of Atrial Fibrillation
Study identifier:D1461C00006
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
Study Complete
Official Title
A double-blind, randomised, placebo-controlled, parallel-group, multicentre, phase II study to assess the efficacy of AZD7009 (AR H065522XX) given intravenously (infusion for 15 or 30 minutes) to patients for conversion of atrial fibrillation
Medical condition
Atrial Fibrillation
Phase
Phase 2
Healthy volunteers
No
Study drug
AZD7009, no generic name available
Sex
All
Actual Enrollment
160
Study type
Interventional
Age
18 Years - 80 Years
Date
Study Start Date: 01 Sept 2005
Primary Completion Date: -
Study Completion Date: 01 May 2006
Study design
Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind
Primary Purpose: Treatment
Verification:
Verified 01 Nov 2013 by AstraZeneca Pharmaceuticals
Sponsors
AstraZeneca Pharmaceuticals
Collaborators
-
Inclusion and exclusion criteria
Loading...
No locations available
| Arms | Assigned Interventions |
|---|
Contacts
Contact
AstraZeneca Clinical Study Information
-
-
Investigators
Principal Investigator
AstraZeneca AZD7009 Midical Science Director
AstraZeneca
